70117-25-8

Basic information

• Product Name: Methyl 5-(bromomethyl)-2-furoate
• Synonyms: Methyl 5-(bromomethyl)-2-furoate
• CAS NO: 70117-25-8
• Molecular Formula: C₇H₇BrO₃
• Molecular Weight: 219.03268
• Mol File: 70117-25-8.mol

Chemical Properties

• Boiling Point: 282.2°C at 760 mmHg
• Flash Point: 124.4°C
• Appearance: /
• Density: 1.568g/cm³
• Vapor Pressure: 0.00342mmHg at 25°C
• Refractive Index: 1.527
• CAS DataBase Reference: Methyl 5-(bromomethyl)-2-furoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-(bromomethyl)-2-furoate(70117-25-8)
• EPA Substance Registry System: Methyl 5-(bromomethyl)-2-furoate(70117-25-8)

Safety Data

• Hazardous Substances Data: 70117-25-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H7BrO3/c1-10-7(9)6-3-2-5(4-8)11-6/h2-3H,4H2,1H3

Upstream product

• 61259-48-1 2,3,4,6-tetra-O-acetyl-D-glucono-1,5-lactone 
• 36802-01-4 Methyl ester of 5-hydroxymethylfuran 2-carboxylic acid 
• 22860-23-7 (2R,3S)-2-[(acetyloxy)methyl]-6-oxo-3,6-dihydro-2H-pyran-3,5-diyl diacetate 
• 90-80-2 D-Glucono-1,5-lactone 
• 2527-96-0 methyl 5-methyl-2-furancarboxylate 
• 620-02-0 5-Methylfurfural 
• 67-56-1 methanol 
• 611-13-2 2-furoic acid methyl ester 
• 50-00-0 formaldehyd 

Downstream Products

• 20450-59-3 1-(5-methoxycarbonyl-2-furyl)-2-(4-nitrophenyl)ethylene 
• 20450-58-2 1-(5-methoxycarbonyl-2-furyl)-2-(4-nitrophenyl)ethylene 
• 74675-61-9 5-[(E)-2-(4-Nitro-phenyl)-1-trichloromethanesulfonyl-vinyl]-furan-2-carboxylic acid methyl ester 
• 74688-62-3 5-[(E)-2-(4-Dimethylamino-phenyl)-1-trichloromethanesulfonyl-vinyl]-furan-2-carboxylic acid methyl ester 
• 74675-62-0 5-[(E)-2-(4-Cyano-phenyl)-1-trichloromethanesulfonyl-vinyl]-furan-2-carboxylic acid methyl ester 
• 74675-66-4 5-[(E)-2-(4-Methoxy-phenyl)-1-trichloromethanesulfonyl-vinyl]-furan-2-carboxylic acid methyl ester 
• 74675-65-3 5-[(E)-2-(4-Hydroxy-phenyl)-1-trichloromethanesulfonyl-vinyl]-furan-2-carboxylic acid methyl ester 
• 74675-64-2 5-[(E)-2-(4-Chloro-phenyl)-1-trichloromethanesulfonyl-vinyl]-furan-2-carboxylic acid methyl ester 
• 74675-63-1 5-[(E)-2-(4-Iodo-phenyl)-1-trichloromethanesulfonyl-vinyl]-furan-2-carboxylic acid methyl ester 
• 74675-60-8 1-(5-methoxycarbonyl-2-furyl)-1-trichlomethylsulfonyl-2-phenylethylene 
• 125343-71-7 5-methoxycarbonyl-2-furfuryltriphenylphosphonium bromide 

Relevant articles and documents

Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio

The farnesoid X receptor (FXR) is a promising therapeutic target for nonalcoholic steatohepatitis (NASH) and other bile acid related diseases because it plays a critical role in fibrosis, inflammation and bile acid homeostasis. Obeticholic acid (OCA), a FXR agonist which was synthesized from chenodeoxycholic acid, showed desirable curative effects in clinical trials. However, the pruritus which was the main side effect of OCA limited its further applications in NASH. Although pruritus was also observed in the clinical trials of non-steroidal FXR agonists, the proportion of patients with pruritus was much smaller than that of OCA. Thus, we decided to develop non-steroidal FXR agonists and discovered a series of novel FXR agonists which were synthesized from GW4064 by replacing the stilbene group with ketoxime ether. Encouragingly, in the following biological tests, our target compounds 13j and 13z not only showed potent FXR agonistic activities in vitro, but also effectively promoted the expression of target genes in vivo. More importantly, in the pharmacokinetic experiments, compounds 13j and 13z displayed high liver/blood ratio characteristics which were helpful to reduce the potential side effects which were caused by prolonged systemic activation of FXR. In summary, our compounds were good choices for the development of non-steroidal FXR agonists and were deserved further investigation.

Scalable synthesis of hydroxymethyl alkylfuranoates as stable 2,5-furandicarboxylic acid precursors

Hydroxymethyl furanoic acid and its derivatives have been synthesized in high yields and purity from gluconolactone. The reaction sequence allows the recovery of reagents and the use of bio-friendly chemicals and solvents, and can easily be scaled up. The reaction product on a >100 gram scale can be purified by a single purification method, such as distillation or precipitation. The overall yield is above 50%.

SYNTHESIS OF PRECURSORS OF 2,5-FURANDICARBOXYLIC ACID

The present invention relates to a method for the manufacture of stable FDCA precursors from saccharide derived starting materials. More specific the invention relates to the synthesis of FDCA precursors such as alkyl 5-(hydroxymethyl)furan-2-carboxylates or 5-(hydroxymethyl)furan-2-carboxylic acid in an expedient, practical and environmental benign manner from e.g. D-glucono-δ-lactone. These bio-based monomer building blocks hold great potential in the manufacture of polymer materials.

Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease

We have identified chemical probes that act as dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors (>1 log unit difference versus class I HDACs) to decipher the contribution of HDAC isoforms to the positive impact of dua

NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES

It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):

QUINOXALINES AS B RAF INHIBITORS

The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

Dipeptide nitriles

N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R2, R3, R4, R5, X1, Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.